IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications

🔗 Access full article via Annals of Oncology

For the treatment of a variety of solid tumors, atezolizumab intravenous ( IV ) is approved. A coformulation of atezolizumab and recombinant human hyaluronidase PH20 was created for subcutaneous( SC ) use in order to enhance treatment convenience and healthcare efficiency. A randomised phase III, open-label, multicenter, noninferiority study in Part 2 of IMscin001( NCT03735121 ) compared the drug exposure of atezolizumab SC and atezezumib IV.